Previsión
| Comprar |
6 |
| Mantener |
2 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Lifeward shareholders approve partnership with Oramed and potential capital injection
Lifeward has approved the issuance of common shares as part of a strategic partnership with Oramed, potentially giving the company access to up to about $47 million from Oramed and an additional investor. The financing includes equity, convertible bonds, milestone payments and warrants. Oramed will manage and fund the clinical development program for the POD technology, which aims to enable oral delivery of biopharmaceuticals, while Lifeward will focus on its medical technology business. Lifeward shares jumped more than 10% after the announcement but remain down around 65% year-to-date; completion of the transaction is still subject to customary conditions. » Más en de.investing.com
Oramed receives $18 million from Scilex and announces cash dividend
Oramed has received a payment of $18 million from Scilex, fulfilling all obligations under an option agreement and raising the total return on the original $99.5 million investment to $118 million. Oramed also retains a $27 million promissory note, a $12 million convertible note (conversion price $36 per share), warrants and a nine‑year royalty/license interest in Scilex products. The board approved a cash dividend of $0.25 per share (ex‑date January 16, 2026; payment January 26, 2026), to be financed from surplus funds; the share price then rose by about 6.2%. » Más en de.investing.com
Oramed Pharmaceuticals: Leonard Sank steps down from director post after 18 years
Leonard Sank has announced he will resign his mandate on the supervisory board of Oramed Pharmaceuticals effective January 1, 2026. The company emphasizes that his resignation is not due to disagreements over management, policies, or practices. Sank served 18 years as a director. » Más en de.investing.com
Oramed completes repurchase of Scilex warrants for $28.5m
Oramed received a total of $28.5 million from Scilex for the repurchase of warrants to acquire 6,500,000 Scilex common shares (two tranches: 3,370,000 shares for $14 million and 3,130,000 shares for $13 million, plus $1.5 million in option fees). The warrants had an exercise price of $0.01 and were repurchased under an agreement disclosed in July. In addition, Oramed repurchased 1,155,367 of its own common shares for about $2.58 million and ended a joint venture with HTIT/Technowl; the company now plans to continue its oral insulin program independently and to initiate a new U.S. study. » Más en de.investing.com
Oramed buys back HTIT shares and ends joint venture
Oramed repurchased 1,155,367 common shares of Hefei Tianhui Biotech (HTIT) at $2.23 each (about $2.58 million) and had the shares cancelled. The company terminated the joint-venture agreement with HTIT and Technowl after HTIT failed to meet closing conditions. Oramed released preliminary, unaudited financials as of September 30, 2025, and launched a new U.S. study for its oral insulin program with 60 identified high responders. It also completed the first tranche of an option repurchase agreement with Scilex (3,130,000 shares for $13 million) and increased the number of authorized shares under its stock option plan by 2,000,000 to 9,500,000. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasEn 2026, Oramed Pharmaceuticals ya ha pagado 0,21 € en dividendos. El último pago fue en enero.
Datos financieros
En el último trimestre, Oramed Pharmaceuticals tuvo unos ingresos de 0 € y un beneficio neto de 16,25 M €
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 0 | - |
| Beneficio bruto | 0 | 100,00 % |
| Beneficio neto | 16,25 M | 60,59 % |
| EBITDA | 24,99 M | 50,69 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 141,48 M € |
Número de acciones | 43,49 M |
Máximo/mínimo de 52 semanas | 4,99 € - 2,30 € |
Rentabilidad por dividendo | 6,00 % |
Dividendos TTM | 0,21 € |
Beta | 1,28 |
Ratio P/E | 1,02 |
Ratio PEG | 0,00 |
Ratio P/B | 0,44 |
Ratio P/S | 0,00 |
Perfil de la empresa
Oramed Pharmaceuticals Inc. se dedica a la investigación y el desarrollo de soluciones farmacéuticas para el tratamiento de la diabetes y para el uso de cápsulas o píldoras ingeribles por vía oral para la administración de polipéptidos. Su producto insignia propietario es el ORMD-0801, una cápsula de insulina ingerible por vía oral, que completó los ensayos clínicos de fase II para el tratamiento de personas con diabetes. También desarrolla el ORMD-0901, una cápsula oral de péptido similar al glucagón-1 que ha completado los ensayos clínicos de fase I para el tratamiento de la diabetes tipo 2; y un tratamiento para la pérdida de peso en forma de cápsula oral de leptina. La empresa era conocida anteriormente como Integrated Security Technologies, Inc. y cambió su nombre a Oramed Pharmaceuticals Inc. en abril de 2006. Oramed Pharmaceuticals Inc. fue fundada en 2002 y tiene su sede en Nueva York, Nueva York.
| Nombre | Oramed Pharmaceuticals |
| CEO | Nadav Kidron |
| Sede | New York City,
ny Estados Unidos |
| Sitio web | |
| Sector | Materiales |
| Industria | Productos químicos |
| Salida a bolsa | 01/05/2007 |
| Empleados | 13 |
Deep Dive
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
Tlv | ORMP.TA |
NASDAQ | ORMP |
Frankfurt | OJU1.F |
Düsseldorf | OJU1.DU |
München | OJU1.MU |